Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer
| Class:Id | LiteratureReference:9925341 |
|---|
| _displayName | MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer |
|---|
| _timestamp | 2024-10-16 18:39:20 |
|---|
| author | [Person:8935857] Yang, Meng
[Person:9924854] Xiao, Ran
[Person:9924906] Wang, Xinru
[Person:9925027] Xiong, Youyi
[Person:9925112] Duan, Zhenfeng
[Person:9925074] Li, Duolu
[Person:9924966] Kan, Quancheng |
|---|
| created | [InstanceEdit:9925315] Tiwari, Krishna, 2024-10-16 |
|---|
| journal | Ann Transl Med |
|---|
| modified | [InstanceEdit:9925426] Tiwari, Krishna, 2024-10-16 |
|---|
| pages | 203 |
|---|
| pubMedIdentifier | 35280383 |
|---|
| title | MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer |
|---|
| volume | 10 |
|---|
| year | 2022 |
|---|
| (literatureReference) | [Summation:9924858] MicroRNA-93 (miR-93) plays a critical role in controlling ce...
[RegulationReference:9924959] Negative regulation by 'CD274 mRNA:miR-93 RISC [cytosol]' MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer
[Reaction:9924908] CD274 mRNA binds miR-93 RISC [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer (9925341)
